Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Dynavax Technologies Corporation discovers, develops, and seeking to commercialize products based on immunostimulatory sequences. The Company developes products to treat and prevent allergies, infectious, and chronic inflammatory diseases using approaches that alter immune system responses in specific ways.
Website: dynavax.com


  • Good financial results growth rate 70.4% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-5.2%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -9.9% (LTM)
  • Share price is 9.7% higher than minimum and 31.5% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (40.6x vs 30.0x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $22.3 mln (-1.728% of cap.)

Key Financials (Download financials)

Ticker: DVAX
Share price, USD:  (+3.4%)10.265
year average price 11.54  


year start price 11.35 2024-10-02

max close price 14.40 2025-03-07

min close price 9.36 2025-09-15

current price 10.26 2025-10-01
Common stocks: 119 317 000

Dividend Yield:  0.0%
FCF Yield LTM: -9.9%
EV / LTM EBITDA: 40.6x
EV / EBITDA annualized: 8.4x
Last revenue growth (y/y):  +28.4%
Last growth of EBITDA (y/y):  +112.5%
Historical revenue growth:  -10.3%
Historical growth of EBITDA:  0.0%
EV / Sales: 1.9x
Margin (EBITDA LTM / Revenue): 4.7%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 1 224
Net Debt ($m): -614
EV (Enterprise Value): 610
EBITDA LTM (млн $): 15
EV / LTM EBITDA: 40.6x
Price to Book: 1.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-09-29seekingalpha.com

3 Of My Favorite Biotech Stocks Under $10

2025-08-11seekingalpha.com

Dynavax Technologies: A Dip To Accumulate

2025-08-07seekingalpha.com

Dynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call Transcript

2025-08-07zacks.com

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates

2025-06-09prnewswire.com

Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

2025-05-23reuters.com

ISS backs Dynavax directors in board fight with Deep Track Capital

2025-05-23prnewswire.com

Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

2025-05-21seekingalpha.com

Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good

2025-05-12prnewswire.com

Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value

2025-05-07prnewswire.com

Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol DVAX DVAX DVAX DVAX DVAX DVAX DVAX DVAX DVAX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-06 2024-05-08 2024-02-22 2023-11-02 2023-08-03 2023-05-02 2023-02-23 2022-11-03
acceptedDate 2024-11-07 16:18:30 2024-08-06 16:10:29 2024-05-08 16:10:55 2024-02-22 16:10:48 2023-11-02 16:15:38 2023-08-03 16:19:48 2023-05-02 16:13:35 2023-02-23 16:22:06 2022-11-03 16:15:50
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 81M 74M 51M 56M 70M 60M 47M 184M 168M
costOfRevenue 13M 12M 11M 9M 13M 14M 15M 77M 61M
grossProfit 68M 62M 40M 47M 56M 47M 32M 107M 106M
grossProfitRatio 0.838 0.838 0.784 0.844 0.81 0.775 0.686 0.58 0.634
researchAndDevelopmentExpenses 14M 15M 14M 14M 14M 13M 14M 13M 13M
generalAndAdministrativeExpenses 43M 42M 44M 41M 38M 37M 37M 31M 32M
sellingAndMarketingExpenses 0 -862 000 -1M -70M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 43M 41M 43M 41M 38M 37M 37M 31M 32M
otherExpenses 0 2M -2M 2M 2M 2M 2M 2M 0
operatingExpenses 57M 56M 56M 55M 52M 50M 50M 44M 45M
costAndExpenses 71M 68M 67M 64M 65M 64M 65M 121M 106M
interestIncome 9M 9M 9M 10M 8M 7M 7M 4M 3M
interestExpense 1M 1M 1M 3M 2M 1M 2M 2M 2M
depreciationAndAmortization 2M 2M 2M 43 812 10M 2M 8M 7M 8M
ebitda 23M 19M -15M 5M 15M 7M -10M 70M 69M
ebitdaratio 0.289 0.109 -0.288 0.099 0.213 0.123 -0.207 0.378 0.411
operatingIncome 10M 6M -17M -8M 5M -3M -18M 63M 61M
operatingIncomeRatio 0.125 0.082 -0.326 -0.153 0.074 -0.057 -0.382 0.342 0.366
totalOtherIncomeExpensesNet 10M 9M 5M 2M 3M 2M -6M 5M 3M
incomeBeforeTax 20M 15M -11M 996 000 14M 4M -24M 68M 64M
incomeBeforeTaxRatio 0.246 0.202 -0.226 0.018 0.203 0.07 -0.505 0.368 0.382
incomeTaxExpense 2M 4M -3M 777 000 -147 000 776 000 616 000 241 000 283 000
netIncome 18M 11M -9M 219 000 14M 3M -24M 68M 64M
netIncomeRatio 0.218 0.154 -0.172 0.004 0.206 0.057 -0.519 0.367 0.38
eps 0.13 0.087 -0.067 0.002 0.11 0.03 -0.19 0.53 0.5
epsdiluted 0.11 0.082 -0.067 0.002 0.093 0.03 -0.19 0.45 0.43
weightedAverageShsOut 131M 131M 130M 129M 129M 129M 128M 128M 127M
weightedAverageShsOutDil 155M 154M 130M 133M 154M 152M 128M 152M 152M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol DVAX DVAX DVAX DVAX DVAX DVAX DVAX DVAX DVAX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-06 2024-05-08 2024-02-22 2023-11-02 2023-08-03 2023-05-02 2023-02-23 2022-11-03
acceptedDate 2024-11-07 16:18:30 2024-08-06 16:10:29 2024-05-08 16:10:55 2024-02-22 16:10:48 2023-11-02 16:15:38 2023-08-03 16:19:48 2023-05-02 16:13:35 2023-02-23 16:22:06 2022-11-03 16:15:50
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 119M 113M 132M 150M 155M 227M 174M 202M 199M
shortTermInvestments 645M 623M 592M 592M 566M 455M 478M 422M 388M
cashAndShortTermInvestments 764M 736M 724M 742M 720M 682M 652M 624M 586M
netReceivables 75M 63M 46M 45M 47M 45M 102M 148M 131M
inventory 62M 62M 62M 53M 49M 53M 58M 59M 103M
otherCurrentAssets 25M 21M 20M 19M 66M 17M 120M 86M 113M
totalCurrentAssets 926M 882M 851M 859M 836M 797M 830M 684M 933M
propertyPlantEquipmentNet 59M 59M 60M 62M 61M 63M 64M 63M 61M
goodwill 2M 2M 2M 2M 2M 2M 2M 2M 2M
intangibleAssets 0 0 1 0 0 0 0 0 0
goodwillAndIntangibleAssets 2M 2M 2M 2M 2M 2M 2M 2M 2M
longTermInvestments 0 270 000 271 000 277 000 266 000 0 0 0 0
taxAssets 0 0 0 -277 000 -266 000 0 0 0 0
otherNonCurrentAssets 74M 73M 73M 74M 74M 74M 74M 237M 4M
totalNonCurrentAssets 136M 134M 135M 138M 137M 139M 140M 302M 66M
otherAssets 0 0 0 0 0 0 0 0 0
totalAssets 1 062M 1 016M 987M 997M 973M 936M 970M 986M 999M
accountPayables 7M 5M 2M 5M 3M 3M 7M 3M 3M
shortTermDebt 0 5M 5M 4M 4M 4M 4M 4M 3M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 52M -4M -4M 0 0 87M
otherCurrentLiabilities 63M 53M 49M 24 000 51M 42M 80M 143M 150M
totalCurrentLiabilities 70M 62M 56M 62M 54M 45M 92M 150M 244M
longTermDebt 250M 251M 223M 252M 253M 254M 254M 254M 254M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 60M 61M 89M 60M 61M 61M 61M 384 000 161M
totalNonCurrentLiabilities 311M 311M 312M 313M 314M 314M 315M 255M 255M
otherLiabilities 0 0 1 0 0 0 0 0 0
capitalLeaseObligations 27M 27M 29M 34M 31M 36M 32M 36M 37M
totalLiabilities 381M 373M 368M 375M 368M 359M 406M 405M 499M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 131 000 131 000 131 000 130 000 129 000 129 000 128 000 128 000 127 000
retainedEarnings -910M -928M -939M -931M -931M -945M -949M -924M -992M
accumulatedOtherComprehensiveIncomeLoss 514 000 -5M -4M -2M -6M -5M -4M -5M -9M
othertotalStockholdersEquity 1 591M 1 576M 1 562M 1 555M 1 542M 1 528M 1 516M 1 511M 1 502M
totalStockholdersEquity 681M 643M 618M 622M 605M 577M 564M 581M 501M
totalEquity 681M 643M 618M 622M 605M 577M 564M 581M 501M
totalLiabilitiesAndStockholdersEquity 1 062M 1 016M 987M 997M 973M 936M 970M 986M 999M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 062M 1 016M 987M 997M 973M 936M 970M 986M 999M
totalInvestments 645M 623M 592M 592M 566M 455M 478M 422M 388M
totalDebt 250M 255M 256M 257M 253M 258M 254M 258M 258M
netDebt 131M 143M 124M 107M 99M 31M 80M 56M 59M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol DVAX DVAX DVAX DVAX DVAX DVAX DVAX DVAX DVAX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-06 2024-05-08 2024-02-22 2023-11-02 2023-08-03 2023-05-02 2023-02-23 2022-11-03
acceptedDate 2024-11-07 16:18:30 2024-08-06 16:10:29 2024-05-08 16:10:55 2024-02-22 16:10:48 2023-11-02 16:15:38 2023-08-03 16:19:48 2023-05-02 16:13:35 2023-02-23 16:22:06 2022-11-03 16:15:50
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 18M 11M -9M 219 000 14M 3M -24M 68M 64M
depreciationAndAmortization 2M 2M 2M 2M 2M 2M 2M 1M 3M
deferredIncomeTax 0 0 0 9M -5M -4M 0 0 0
stockBasedCompensation 13M 14M 13M 11M 11M 11M 10M 9M 9M
changeInWorkingCapital -12M -11M -26M 7M 8M 17M 30M -59M -27M
accountsReceivables -13M -16M -2M -18M 6M 17M -5M 27M 0
inventory 12M -656 000 -10M -6M 3M 5M 2M 23M -43M
accountsPayables 3M 2M -3M 3M -461 000 -4M 4M 390 000 -2M
otherWorkingCapital -13M 4M -12M 28M -659 000 -660 000 29M -110M 18M
otherNonCashItems -2M 27M 34M -15M 2M -1M 11M 16M 13M
netCashProvidedByOperatingActivities 19M 11M -17M 14M 31M 28M 28M 35M 62M
investmentsInPropertyPlantAndEquipment -1M -779 000 -749 000 -2M -347 000 -751 000 -1M -2M -1M
acquisitionsNet 0 0 0 1 000 000 1 000 000 0 0 0 0
purchasesOfInvestments -165M -175M -151M -153M -225M -74M -185M -118M -201M
salesMaturitiesOfInvestments 151M 147M 154M 134M 118M 100M 134M 86M 83M
otherInvestingActivites 0 0 0 -1 000 000 0 0 0 0 0
netCashUsedForInvestingActivites -15M -29M 3M -20M -106M 25M -52M -33M -119M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued -3M 419 000 3M 486 000 3M 0 1M 10M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 2M -1M -7M 1M -486 000 -294 000 -4M -9M 8M
netCashUsedProvidedByFinancingActivities 2M -1M -4M 2M 3M -294 000 -3M 153 000 8M
effectOfForexChangesOnCash 363 000 -64 000 -201 000 479 000 -305 000 -1000 151 000 1M -1M
netChangeInCash 7M -20M -18M -4M -72M 52M -28M 3M -51M
cashAtEndOfPeriod 120M 113M 132M 151M 155M 227M 175M 202M 199M
cashAtBeginningOfPeriod 113M 132M 150M 155M 227M 175M 202M 199M 249M
operatingCashFlow 19M 11M -17M 14M 31M 28M 28M 35M 62M
capitalExpenditure -1M -779 000 -749 000 -2M -347 000 -751 000 -1M -2M -1M
freeCashFlow 18M 10M -17M 12M 31M 27M 26M 33M 60M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-07 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-08 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-02 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-29 12:30 ET
Dynavax Adopts Limited-Duration Stockholder Rights Plan
2024-10-24 20:10 ET
Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024
2024-08-06 20:01 ET
Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates
2024-07-23 20:00 ET
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
2024-06-27 20:09 ET
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
2024-05-28 20:18 ET
Dynavax to Present at Upcoming Investor Conferences
2024-05-14 12:30 ET
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
2024-05-08 20:01 ET
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
2024-04-24 20:05 ET
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
2024-02-27 23:54 ET
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
2024-02-22 21:01 ET
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
2024-02-08 21:15 ET
Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024
2024-01-08 14:00 ET
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
2024-01-03 23:33 ET
Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-20 22:04 ET
Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference
2023-11-02 20:01 ET
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
2023-10-26 20:15 ET
Dynavax to Report Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
2023-10-19 17:15 ET
Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference
2023-09-06 20:05 ET
Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-03 20:05 ET
Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
2023-07-20 20:15 ET
Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023
2023-05-30 20:15 ET
Dynavax to Present at Upcoming Investor Conferences
2023-05-08 20:15 ET
Dynavax to Present at the JMP Securities Life Sciences Conference
2023-05-02 20:05 ET
Dynavax Reports First Quarter 2023 Financial Results
2023-04-18 20:15 ET
Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023
2023-03-01 21:15 ET
Dynavax to Present at the Cowen 43rd Annual Health Care Conference
2023-02-28 13:00 ET
Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine
2023-02-23 21:05 ET
Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance
2023-02-09 21:15 ET
Dynavax to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
2023-01-31 21:15 ET
Dynavax Announces Uplisting to the Nasdaq Global Select Market
2023-01-09 13:00 ET
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results
2022-11-09 21:05 ET
Dynavax to Present at Two Upcoming Investor Conferences
2022-11-03 20:05 ET
Dynavax Reports Third Quarter 2022 Financial Results
2022-10-20 20:05 ET
Dynavax to Report Third Quarter Financial Results and Host Conference Call on November 3, 2022
2022-10-14 20:05 ET
Dynavax to Present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual Conference
2022-09-12 12:00 ET
Dynavax Announces First Participant Dosed in a Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine
2022-09-08 20:05 ET
Dynavax to Present at the H.C. Wainwright 24th Annual Global Investment Conference
2022-08-04 20:02 ET
Dynavax Reports Second Quarter 2022 Financial Results
2022-07-21 20:05 ET
Dynavax to Report Second Quarter Financial Results and Host Conference Call on August 4, 2022
2022-05-25 20:05 ET
Dynavax to Present at the William Blair 42nd Annual Growth Stock Conference
2022-05-16 20:10 ET
Dynavax to Present at the H.C. Wainwright Global Investment Conference
2022-05-12 22:16 ET
Independence Realty Trust Set to Join S&P MidCap 400; Alpha and Omega Semiconductor & Dynavax Technologies to Join S&P SmallCap 600
2022-05-05 20:02 ET
Dynavax Reports First Quarter 2022 Financial Results
2022-04-21 20:05 ET
Dynavax to Report First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022
2022-04-05 20:02 ET
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-03-03 21:05 ET
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-02-28 21:02 ET
Dynavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Financial Guidance
2022-02-23 21:05 ET
Dynavax to Present at the Cowen 42nd Annual Health Care Conference
2022-02-16 21:05 ET
Dynavax to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022
2022-02-02 21:05 ET
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-01-10 13:00 ET
Dynavax Highlights 2022 Priorities and Announces Initiation of Phase 1 Clinical Trial for Its Shingles Vaccine Candidate
2022-01-07 21:05 ET
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-01-05 21:05 ET
Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
2021-12-28 16:34 ET
COVID-19 Vaccine Developed by Biological E Using Dynavax's CpG 1018 Adjuvant Receives India DCGI Approval for Emergency Use
2021-12-14 13:10 ET
Elaine D. Sun Appointed to Dynavax Board of Directors
2021-12-02 21:05 ET
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-11-18 21:10 ET
Dynavax to Present at the 4th Annual Evercore Virtual ISI HealthCONx Conference
2021-11-04 20:02 ET
Dynavax Reports Third Quarter 2021 Financial Results
2021-11-02 20:10 ET
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-10-21 20:20 ET
Scott Myers Appointed to Dynavax Board of Directors and Elected Board Chairman
2021-10-21 12:00 ET
Dynavax to Report Third Quarter 2021 Financial Results and Host Conference Call on November 4, 2021
2021-10-18 21:43 ET
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-10-04 12:00 ET
Dynavax and U.S. Department of Defense Announce Collaboration to Develop an Adjuvanted Plague Vaccine Using Dynavax's CpG 1018 Adjuvant
2021-10-01 22:13 ET
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-09-27 20:20 ET
Dynavax to Present at Upcoming Investment Conferences
2021-09-22 11:08 ET
COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial
2021-09-09 20:02 ET
Dynavax to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-02 20:02 ET
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-08-23 12:00 ET
Medigen Vaccine Biologics Announces Launch of Its COVID-19 Vaccine MVC-COV1901 Adjuvanted with Dynavax's CpG 1018 Adjuvant
2021-08-04 20:02 ET
Dynavax Announces Second Quarter 2021 Financial Results
2021-08-03 20:10 ET
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-07-21 20:02 ET
Dynavax to Report Second Quarter 2021 Financial Results and Host Conference Call on August 4, 2021
2021-07-06 12:00 ET
Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate
2021-07-02 20:05 ET
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-06-30 08:00 ET
Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate
2021-06-29 20:05 ET
Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2021-06-09 20:05 ET
Dynavax to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
2021-05-27 11:00 ET
Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany
2021-05-19 20:05 ET
Dynavax to Present at the William Blair 41st Annual Growth Stock Conference
2021-05-11 11:30 ET
Dynavax Announces Pricing of $200 Million Convertible Senior Notes Offering
2021-05-10 11:10 ET
Dynavax Announces Proposed Private Offering of $200 Million of Convertible Senior Notes
2021-05-06 20:02 ET
Dynavax Announces First Quarter 2021 Financial Results
2021-05-04 20:01 ET
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-04-27 12:00 ET
HEPLISAV-B Post-Marketing Observational Study Results Presented at 2021 Annual Conference on Vaccinology Research (ACVR)
2021-04-22 20:05 ET
Dynavax to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021
2021-04-21 20:01 ET
Valneva Initiates Pivotal Phase 3 Clinical Trial for its Inactivated, COVID-19 Vaccine Candidate using Dynavax's CpG 1018™ Adjuvant
2021-04-19 20:10 ET
Two HEPLISAV-B Abstracts Selected for Oral Presentation at the 2021 Annual Conference on Vaccinology Research (ACVR)
2021-04-06 10:00 ET
Positive Phase 1/2 Results for Valneva's Inactivated COVID-19 Vaccine Candidate Using Dynavax's CpG 1018™ Adjuvant
2021-04-02 20:05 ET
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-03-24 06:15 ET
Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate
2021-03-01 21:15 ET
Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference
2021-03-01 21:14 ET
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-02-25 21:02 ET
Dynavax Announces Fourth Quarter and Full Year 2020 Financial Results
2021-02-19 17:20 ET
Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine
2021-02-16 21:05 ET
Dynavax to Present at the Cowen 41st Annual Health Care Conference
2021-02-11 21:05 ET
Dynavax to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 25, 2021
2021-02-08 21:13 ET
Dong Yu, Ph.D., Joins Dynavax as Senior Vice President of Vaccine Research
2021-02-04 21:05 ET
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-02-04 13:00 ET
Dynavax and Serum Institute of India Announce First Participant Dosed in a Phase 1 Clinical Trial Evaluating an Improved Tdap Vaccine Adjuvanted with CpG 1018
2021-02-01 12:02 ET
Dynavax Announces Exercise of Option to Reserve Additional CpG 1018 to Produce 40 Million Doses of Valneva's Inactivated, Adjuvanted COVID-19 Vaccine Candidate for the UK Government
2021-02-01 12:01 ET
Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response
2021-02-01 06:00 ET
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate
2021-02-01 06:00 ET
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
2021-01-25 13:00 ET
Medigen Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan
2021-01-20 21:05 ET
Dynavax Appoints Kelly MacDonald as Chief Financial Officer
2021-01-07 13:00 ET
Dynavax Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis
2021-01-06 21:05 ET
Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
2020-12-23 13:00 ET
Serum Institute Of India And Dynavax Announce First Participants Dosed In The Phase 1/2 Clinical Trial For A COVID-19 Vaccine
2020-12-10 21:05 ET
European CHMP Adopts Positive Opinion for HEPLISAV-B®, Dynavax's Two Dose Adult Hepatitis B Adjuvanted Vaccine
2020-12-04 08:00 ET
Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates
2020-11-17 21:05 ET
Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference
2020-11-16 11:00 ET
Biological E. Limited Starts Phase I/II Clinical Trial of its COVID-19 Vaccine Candidate
2020-11-05 21:01 ET
Dynavax Announces Third Quarter 2020 Financial Results
2020-11-02 21:05 ET
Dynavax to Present at the Stifel 2020 Virtual Healthcare Conference
2020-10-22 20:05 ET
Dynavax to Report Third Quarter 2020 Financial Results and Host Conference Call on November 5, 2020
2020-10-13 10:00 ET
Medigen's COVID-19 Vaccine Combined with Dynavax's CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October
2020-09-25 07:00 ET
Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate
2020-09-24 20:05 ET
Dynavax Announces Appointment of New Board Member and Planned Retirement of Chief Financial Officer
2020-09-14 05:00 ET
Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 Vaccine
2020-08-31 20:10 ET
Dynavax to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference
2020-08-13 12:00 ET
Dynavax Announces Grant to Scale up CpG 1018 Adjuvant Capacity to Support the Global COVID-19 Response
2020-08-06 20:02 ET
Dynavax Announces Second Quarter 2020 Financial Results
2020-08-03 12:00 ET
TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales
2020-07-30 20:05 ET
Dynavax to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020
2020-07-23 12:00 ET
Dynavax and Medigen Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Vaccine Candidate
2020-07-21 20:10 ET
Dynavax Announces the Appointment of Two New Board Members
2020-07-16 12:40 ET
Dynavax and Mount Sinai Announce Collaboration to Develop a Universal Influenza Vaccine Candidate with CpG 1018 Adjuvant
2020-07-14 12:00 ET
Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Medicago’s COVID-19 Vaccine Candidate with Dynavax’s CpG 1018 Adjuvant
2020-07-10 20:01 ET
Dynavax and Times Pharmacy Announce Partnership to Offer HEPLISAV-B® Hepatitis B Vaccine to Customers Throughout Oahu, with a Focus on People with Diabetes
2020-07-08 12:30 ET
Dynavax and Medicago Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Vaccine Candidate
2020-06-22 13:00 ET
Dynavax to Present at the H.C. Wainwright Virtual Fireside Chat Series
2020-06-19 10:00 ET
Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Clover Biopharmaceuticals’ COVID-19 S-Trimer Vaccine Candidate with CpG 1018 Adjuvant
2020-06-09 12:00 ET
Dynavax Completes Enrollment of Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis
2020-05-28 20:05 ET
Dynavax to Present at the William Blair 40th Annual Growth Stock Conference
2020-05-27 20:05 ET
Dynavax Technologies Announces Closing of $80.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2020-05-22 01:00 ET
Dynavax Technologies Announces Pricing of $70.0 Million Public Offering of Common Stock
2020-05-21 20:01 ET
Dynavax Technologies Announces Proposed Public Offering of Common Stock
2020-05-07 20:10 ET
Dynavax Announces First Quarter 2020 Financial Results
2020-04-28 20:10 ET
Dynavax Reports Interim Analysis of Ongoing Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis
2020-04-23 20:10 ET
Dynavax to Report First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020
2020-04-16 11:30 ET
Dynavax and Sinovac Announce Collaboration to Develop a Coronavirus (COVID-19) Vaccine
2020-04-16 11:30 ET
Dynavax and Sinovac Announce Collaboration to Develop a Coronavirus (COVID-19) Vaccine
2020-04-08 12:00 ET
Dynavax Donates 10,000 Doses of HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Vaccine to Emergency Healthcare Providers and Hospital Staff to Protect Against Hepatitis B Infections Amidst COVID-19 Pandemic
2020-04-02 20:30 ET
Dynavax Provides Business Update on COVID-19 Pandemic Impact
2020-03-26 11:30 ET
Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)
2020-03-26 11:30 ET
Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)
2020-03-24 12:30 ET
Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant
2020-03-24 12:30 ET
Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant
2020-03-11 20:10 ET
Dynavax Announces Fourth Quarter and Full Year 2019 Financial Results
2020-03-02 13:00 ET
Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Preparedness (CEPI) Focused on the Development of a Coronavirus (COVID-19) Vaccine
2020-02-24 21:05 ET
Dynavax to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11
2020-02-18 21:05 ET
Dynavax to Present at the Cowen 40th Annual Health Care Conference
2019-12-16 21:15 ET
Dynavax Appoints Ryan Spencer as Chief Executive Officer and to Board of Directors
2019-12-05 13:00 ET
Dynavax Announces Partnership with Albertsons Companies’ Pharmacies to Offer HEPLISAV-B® Hepatitis B Vaccine to Patients Nationwide
2019-12-03 12:00 ET
Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed
2019-11-07 21:05 ET
Dynavax to Present at the Stifel 2019 Healthcare Conference
2019-11-06 21:05 ET
Dynavax Announces Third Quarter 2019 Financial Results
2019-10-24 20:05 ET
Dynavax to Report Third Quarter 2019 Financial Results and Host Conference Call on November 6
2019-09-30 20:05 ET
Dynavax to Present at the 2019 Cantor Global Healthcare Conference
2019-04-18 20:05 ET
Dynavax to Present Data on Toll-like Receptor 9 Agonist SD-101 at the ASCO Annual Meeting 2019
2019-04-02 17:00 ET
Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting
2019-04-01 17:00 ET
Dynavax’s SD-101 and 4SC’s Domatinostat Demonstrate Synergy and Induce a Systemic Anti-tumor Response in Preclinical Models
2019-02-11 12:20 ET
Recent Analysis Shows Corcept Therapeutics, CDK Global, Dynavax Technologies, ICU Medical, American Vanguard, and Cabot Market Influences — Renewed Outlook, Key Drivers of Growth

SEC forms

Show financial reports only

SEC form 10
2025-08-07 20:14 ET
Dynavax Technologies reported for 2025 q2
SEC form 8
2025-08-07 20:03 ET
Dynavax Technologies reported for 2025 q2
SEC form 8
2025-08-07 20:03 ET
Dynavax Technologies published news for 2025 q2
SEC form 10
2025-05-06 20:16 ET
Dynavax Technologies published news for 2025 q1
SEC form 8
2025-05-06 20:03 ET
Dynavax Technologies reported for 2025 q1
SEC form 8
2025-05-06 20:03 ET
Dynavax Technologies published news for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Dynavax Technologies published news for 2025 q1
SEC form 10
2025-02-20 16:15 ET
Dynavax Technologies published news for 2024 q4
SEC form 8
2025-02-20 16:03 ET
Dynavax Technologies reported for 2024 q4
SEC form 8
2025-02-20 16:03 ET
Dynavax Technologies published news for 2024 q4
SEC form 8
2025-02-20 02:49 ET
Dynavax Technologies published news for 2024 q4
SEC form 8
2025-02-20 02:49 ET
Dynavax Technologies published news for 2024 q4
SEC form 10
2025-02-20 00:00 ET
Dynavax Technologies published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Dynavax Technologies published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Dynavax Technologies published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Dynavax Technologies published news for 2024 q4
SEC form 10
2024-11-07 16:18 ET
Dynavax Technologies reported for 2024 q3
SEC form 8
2024-11-07 16:12 ET
Dynavax Technologies reported for 2024 q3
SEC form 8
2024-11-07 16:12 ET
Dynavax Technologies published news for 2024 q3
SEC form 10
2024-08-06 16:10 ET
Dynavax Technologies reported for 2024 q2
SEC form 8
2024-08-06 16:05 ET
Dynavax Technologies published news for 2024 q2
SEC form 8
2024-08-06 16:05 ET
Dynavax Technologies reported for 2024 q2
SEC form 10
2024-08-06 00:00 ET
Dynavax Technologies published news for 2024 q2
SEC form 8
2024-05-08 00:00 ET
Dynavax Technologies published news for 2024 q1
SEC form 10
2024-05-08 00:00 ET
Dynavax Technologies reported for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Dynavax Technologies reported for 2024 q1
SEC form 10
2024-02-22 16:10 ET
Dynavax Technologies reported for 2023 q4
SEC form 8
2024-02-22 16:05 ET
Dynavax Technologies published news for 2023 q4
SEC form 8
2024-02-22 16:05 ET
Dynavax Technologies reported for 2023 q4
SEC form 10
2024-02-22 00:00 ET
Dynavax Technologies published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Dynavax Technologies published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Dynavax Technologies published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Dynavax Technologies published news for 2023 q4
SEC form 10
2023-11-02 16:15 ET
Dynavax Technologies reported for 2023 q3
SEC form 8
2023-11-02 16:10 ET
Dynavax Technologies reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Dynavax Technologies published news for 2023 q3
SEC form 10
2023-08-03 16:19 ET
Dynavax Technologies reported for 2023 q2
SEC form 6
2023-08-03 16:11 ET
Dynavax Technologies reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Dynavax Technologies published news for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Dynavax Technologies published news for 2023 q2
SEC form 6
2023-07-05 16:05 ET
Dynavax Technologies published news for 2023 q2
SEC form 8
2023-05-02 00:00 ET
Dynavax Technologies published news for 2023 q1
SEC form 10
2023-05-02 00:00 ET
Dynavax Technologies published news for 2023 q1
SEC form 10
2023-02-23 16:22 ET
Dynavax Technologies published news for 2022 q4
SEC form 6
2023-02-23 16:13 ET
Dynavax Technologies published news for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Dynavax Technologies reported for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Dynavax Technologies reported for 2022 q4
SEC form 6
2023-01-09 08:11 ET
Dynavax Technologies published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Dynavax Technologies published news for 2022 q4
SEC form 10
2022-11-03 16:15 ET
Dynavax Technologies published news for 2022 q3
SEC form 6
2022-11-03 16:10 ET
Dynavax Technologies published news for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Dynavax Technologies reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Dynavax Technologies reported for 2022 q3
SEC form 6
2022-08-04 16:09 ET
Dynavax Technologies published news for 2022 q2
SEC form 10
2022-08-04 16:07 ET
Dynavax Technologies published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Dynavax Technologies reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Dynavax Technologies reported for 2022 q2
SEC form 6
2022-05-26 16:11 ET
Dynavax Technologies published news for 2022 q1
SEC form 10
2022-05-05 16:13 ET
Dynavax Technologies published news for 2022 q1
SEC form 6
2022-05-05 16:04 ET
Dynavax Technologies published news for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Dynavax Technologies reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Dynavax Technologies reported for 2022 q1
SEC form 6
2022-04-14 16:16 ET
Dynavax Technologies published news for 2022 q1
SEC form 6
2022-03-16 16:41 ET
Dynavax Technologies published news for 2021 q4
SEC form 10
2022-02-28 16:12 ET
Dynavax Technologies published news for 2021 q4
SEC form 6
2022-02-28 16:07 ET
Dynavax Technologies published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Dynavax Technologies published news for 2021 q4
SEC form 8
2022-02-28 00:00 ET
Dynavax Technologies published news for 2021 q4
SEC form 6
2021-12-14 16:05 ET
Dynavax Technologies published news for 2021 q3
SEC form 10
2021-11-04 16:58 ET
Dynavax Technologies published news for 2021 q3
SEC form 6
2021-11-04 16:50 ET
Dynavax Technologies published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Dynavax Technologies published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Dynavax Technologies published news for 2021 q3
SEC form 6
2021-10-21 16:31 ET
Dynavax Technologies published news for 2021 q3
SEC form 10
2021-08-04 17:10 ET
Dynavax Technologies published news for 2021 q2
SEC form 6
2021-08-04 16:06 ET
Dynavax Technologies published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Dynavax Technologies published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
Dynavax Technologies published news for 2021 q2
SEC form 6
2021-07-07 16:05 ET
Dynavax Technologies published news for 2021 q2
SEC form 6
2021-07-01 16:17 ET
Dynavax Technologies published news for 2021 q2
SEC form 6
2021-06-24 16:10 ET
Dynavax Technologies published news for 2021 q1
SEC form 6
2021-06-02 16:50 ET
Dynavax Technologies published news for 2021 q1
SEC form 6
2021-05-26 16:05 ET
Dynavax Technologies published news for 2021 q1
SEC form 6
2021-05-13 16:38 ET
Dynavax Technologies published news for 2021 q1
SEC form 10
2021-05-06 16:13 ET
Dynavax Technologies published news for 2021 q1
SEC form 6
2021-05-06 16:08 ET
Dynavax Technologies published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Dynavax Technologies published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Dynavax Technologies published news for 2021 q1
SEC form 6
2021-05-05 08:57 ET
Dynavax Technologies published news for 2021 q1
SEC form 6
2021-04-16 16:28 ET
Dynavax Technologies published news for 2021 q1
SEC form 6
2021-04-06 16:11 ET
Dynavax Technologies published news for 2021 q1
SEC form 10
2021-02-25 16:11 ET
Dynavax Technologies published news for 2020 q4
SEC form 6
2021-02-25 16:07 ET
Dynavax Technologies published news for 2020 q4
SEC form 6
2021-02-19 14:07 ET
Dynavax Technologies published news for 2020 q4
SEC form 6
2021-02-01 08:10 ET
Dynavax Technologies published news for 2020 q4
SEC form 6
2021-01-21 09:01 ET
Dynavax Technologies published news for 2020 q4
SEC form 6
2021-01-12 16:24 ET
Dynavax Technologies published news for 2020 q4
SEC form 6
2021-01-07 16:10 ET
Dynavax Technologies published news for 2020 q4
SEC form 10
2020-11-05 16:16 ET
Dynavax Technologies published news for 2020 q3
SEC form 6
2020-11-05 16:08 ET
Dynavax Technologies published news for 2020 q3